Acquisition Pending
Servier acquisition of Day One Biopharmaceuticals
US$2.5bn equity value
Announced 6 Mar 2026 · NASDAQ: DAWN · US$21.50 cash per share
Advisers
Day One Biopharmaceuticals
Target
- Financial adviser
- Legal adviser
- Fairness opinion
Servier
Acquirer
- Financial adviser
- Legal adviser
- Information Agent
- Target
- Day One Biopharmaceuticals
- Acquirer
- Servier
- Target based in
- United States
- Buyer based in
- France
- Sector
- Biotech
- Tags
- Biotech, Oncology, Pharma
In the league tables
Similar deals
- HealthCare Royalty acquisition of Modeyso commercial sales royalties Apr 2026 · Specialty finance and leasing
- Eli Lilly and Company acquisition of Orna Therapeutics Feb 2026 · US$2.4bn · Biotech
- Sanofi acquisition of Dynavax Technologies Dec 2025 · US$2.2bn · Biotech
- Eli Lilly and Company acquisition of Ajax Therapeutics Apr 2026 · US$2.3bn · Biotech
- Neurocrine Biosciences acquisition of Soleno Therapeutics Apr 2026 · US$2.9bn · Biotech
Sources
- 2026 Centerview Partners: Exclusive financial advisor to Day One on its sale to Servier centerviewpartners.com
- 6 Mar 2026 Target tender offer communication (SC14D9C), Mersana Therapeutics, Inc. sec.gov
- 6 Mar 2026 Tender offer communication (SC TO-C), Mersana Therapeutics, Inc. sec.gov
- 6 Mar 2026 Press release (EX-99.1, exhibit), Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology sec.gov
- 26 Mar 2026 Tender offer statement (SC TO-T), Mersana Therapeutics, Inc. sec.gov
- 26 Mar 2026 Target response to tender offer (SC 14D9), Mersana Therapeutics, Inc. sec.gov


